{"id":27094,"date":"2026-09-03T15:41:52","date_gmt":"2026-09-03T19:41:52","guid":{"rendered":"https:\/\/www.emilysentourage.org\/?p=27094"},"modified":"2026-09-03T16:14:31","modified_gmt":"2026-09-03T20:14:31","slug":"new-emilys-entourage-grant-to-fund-novel-phage-based-therapy-for-drug-resistant-infections-in-cystic-fibrosis","status":"publish","type":"post","link":"https:\/\/www.emilysentourage.org\/fr_ca\/new-emilys-entourage-grant-to-fund-novel-phage-based-therapy-for-drug-resistant-infections-in-cystic-fibrosis\/","title":{"rendered":"Nouvelle subvention d'Emily's Entourage pour financer une th\u00e9rapie innovante \u00e0 base de phages pour les infections r\u00e9sistantes aux m\u00e9dicaments dans la mucoviscidose"},"content":{"rendered":"

Inhaled bacteriophage-antibiotic combination could offer a new treatment approach for persistent, antibiotic-resistant lung infections<\/span><\/i><\/p>\n

\"\"

Emily’s Entourage (EE) has awarded its fourth 2026 Translational Research Grant to David T. Pride, MD, PhD, Professor of Pathology and Medicine at the University of California San Diego School of Medicine.<\/p><\/div>\n

Lower Merion, PA\u2014September 3, 2026\u2014<\/span>Emily\u2019s Entourage (EE), an innovative 501(c)(3) organization accelerating research for individuals with cystic fibrosis (CF) who do not benefit from current mutation-targeted therapies, is proud to announce its fourth<\/span> 2026 Translational Research Grant awarded to David T. Pride, MD, PhD, Professor of Pathology and Medicine at the University of California San Diego School of Medicine.<\/span><\/p>\n

Dr. Pride\u2019s project aims to develop a novel inhaled therapy combining bacteriophages\u2014viruses that specifically target and kill bacteria\u2014with the antibiotic meropenem to treat persistent lung infections in people with CF that are resistant to standard antimicrobial therapies.<\/span><\/p>\n

Chronic infections and the development of antibiotic resistance pose a major threat to people with CF, driving disease progression and mortality. Among the most challenging of these infections is <\/span>Achromobacter xylosoxidans<\/span><\/i>, a pathogen that can persist in the CF lung despite repeated antibiotic treatment and frequently develops multidrug-resistant (MDR) or extensively drug-resistant (XDR) profiles, leaving people with CF with limited therapeutic options.<\/span><\/p>\n

Dr. Pride and his team have identified a large and diverse collection of bacteriophages capable of targeting and killing <\/span>Achromobacter<\/span><\/i>, with activity observed across a wide range of MDR and XDR clinical isolates. Building on this work, they have made a key discovery: when certain phages are combined with the antibiotic meropenem, the two work synergistically to eliminate the bacteria, even in cases where the bacteria are initially resistant to the antibiotic. This finding suggests a new approach to treatment, in which antibiotic effectiveness may be restored through combinations with phage therapy, expanding treatment options for resistant infections.<\/span><\/p>\n

The team will investigate the biological mechanisms underlying this synergy to better understand how and why this approach is effective.<\/span><\/p>\n

\"<\/span>Achromobacter<\/span><\/i> infections are particularly difficult to treat because of their ability to develop and maintain resistance to multiple antibiotics,\u201d said Dr. Pride. \u201cBy combining bacteriophages with existing antibiotics, we have the potential to restore antibiotic activity and provide a new treatment option for people with CF who have exhausted conventional antibiotic therapies.\u201d<\/span><\/p><\/blockquote>\n

Approximately 10% of people with CF do not benefit from current CFTR modulators and often face a disproportionate burden of chronic, treatment-resistant infections. EE is committed to advancing research that addresses both the underlying genetic causes of CF and the serious issues that continue to impact those living with CF.<\/span><\/p>\n

\u201cThis project represents an innovative and urgently needed approach to addressing antibiotic-resistant infections in CF,\u201d said Chandra Ghose, PhD, Chief Scientific Officer at EE. \u201cBy leveraging the unique ability of bacteriophages to target resistant bacteria\u2014and combining them with existing antibiotics to restore their antimicrobial effects\u2014this work has the potential to expand treatment options for individuals facing some of the most difficult-to-treat infections.\u201d<\/span><\/p>\n

 <\/p><\/blockquote>\n

\u00c0 propos du programme de subventions de l'Entourage d'Emily (EE)<\/b><\/p>\n

Le programme de subventions d'Emily's Entourage (EE) fournit des financements pour acc\u00e9l\u00e9rer la recherche et le d\u00e9veloppement th\u00e9rapeutique pour les personnes atteintes de fibrose kystique (FK) qui ne b\u00e9n\u00e9ficient pas des th\u00e9rapies cibl\u00e9es sur les mutations existantes. EE soutient une gamme de m\u00e9canismes de financement, notamment des subventions translationnelles, des subventions collaboratives et des subventions exploratoires pr\u00e9cliniques, ainsi que des investissements en capital-risque philanthropique.<\/span><\/p>\n

\u00c0 ce jour, EE a octroy\u00e9 des millions de dollars \u00e0 des \u00e9quipes pluridisciplinaires \u00e0 travers le monde et a aid\u00e9 \u00e0 obtenir des millions de plus en financements compl\u00e9mentaires. Pour consulter les subventions accord\u00e9es, visitez <\/span>https:\/\/www.emilysentourage.org\/awarded-grants\/<\/span><\/a>. Pour en savoir plus sur les possibilit\u00e9s de financement de l'EE, consultez le site suivant <\/span>https:\/\/www.emilysentourage.org\/funding-opportunities\/<\/span><\/a>.<\/span><\/p>\n

\u00c0 propos de l'entourage d'Emily<\/b><\/p>\n

Emily\u2019s Entourage (EE) est une organisation innovante de type 501(c)3 qui acc\u00e9l\u00e8re la recherche de nouveaux traitements et d\u2019un rem\u00e8de pour les personnes atteintes de mucoviscidose qui ne tirent aucun b\u00e9n\u00e9fice des th\u00e9rapies cibl\u00e9es sur les mutations actuellement disponibles. Depuis 2011, EE a octroy\u00e9 des millions de dollars de subventions de recherche, lanc\u00e9 une entreprise sp\u00e9cialis\u00e9e dans la th\u00e9rapie g\u00e9nique de la mucoviscidose au stade clinique, d\u00e9velopp\u00e9 la base de donn\u00e9es de patients \u00ab Clinical Trial Connect \u00bb (CTC) ainsi qu\u2019un programme de mise en relation avec des essais cliniques afin d\u2019acc\u00e9l\u00e9rer le recrutement \u00e0 l\u2019\u00e9chelle mondiale pour ces essais, et men\u00e9 des initiatives internationales visant \u00e0 promouvoir la recherche \u00e0 fort impact et le d\u00e9veloppement de m\u00e9dicaments. L\u2019organisation a fait l\u2019objet de reportages dans les m\u00e9dias nationaux, notamment le New York Times, STAT, CNN, People et bien d\u2019autres. Pour en savoir plus, rendez-vous sur <\/span>emilysentourage.org<\/span><\/a>.<\/span><\/p>\n

Contact presse<\/b><\/p>\n

Hannah Kleckner<\/span><\/p>\n

Directeur du marketing et de la communication<\/span><\/p>\n

hannah@emilysentourage.org<\/span><\/p>\n



<\/p>","protected":false},"excerpt":{"rendered":"

Inhaled bacteriophage-antibiotic combination could offer a new treatment approach for persistent, antibiotic-resistant lung infections Lower Merion, PA\u2014September 3, 2026\u2014Emily\u2019s Entourage (EE), an innovative 501(c)(3) organization accelerating research for individuals with cystic fibrosis (CF) who do not benefit from current mutation-targeted therapies, is proud to announce its fourth 2026 Translational Research Grant awarded to David T…. <\/p>\n

<\/div>\n

Lire la suite<\/a><\/p>","protected":false},"author":1719,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_seopress_titles_title":"New Emily\u2019s Entourage Grant to Fund Novel Phage-Based Therapy for Drug-Resistant Infections in Cystic Fibrosis","_seopress_titles_desc":"","_seopress_robots_index":"","_seopress_robots_follow":"","_seopress_robots_imageindex":"","_seopress_robots_snippet":"","_seopress_robots_primary_cat":"","_seopress_robots_breadcrumbs":"","_seopress_robots_freeze_modified_date":"","_seopress_robots_custom_modified_date":"","_seopress_robots_canonical":"","_seopress_social_fb_title":"","_seopress_social_fb_desc":"","_seopress_social_fb_img":"","_seopress_social_fb_img_attachment_id":0,"_seopress_social_fb_img_width":0,"_seopress_social_fb_img_height":0,"_seopress_social_twitter_title":"","_seopress_social_twitter_desc":"","_seopress_social_twitter_img":"","_seopress_social_twitter_img_attachment_id":0,"_seopress_social_twitter_img_width":0,"_seopress_social_twitter_img_height":0,"_seopress_redirections_value":"","_seopress_redirections_enabled":"","_seopress_redirections_enabled_regex":"","_seopress_redirections_logged_status":"","_seopress_redirections_param":"","_seopress_redirections_type":0,"_seopress_analysis_target_kw":"","_seopress_news_disabled":"","_seopress_video_disabled":"","_seopress_video":[],"_seopress_pro_schemas_manual":[],"_seopress_pro_rich_snippets_disable_all":"","_seopress_pro_rich_snippets_disable":[],"_seopress_pro_schemas":[],"_monsterinsights_skip_tracking":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[178],"tags":[197,217,223,204,270,189],"class_list":["post-27094","post","type-post","status-publish","format-standard","hentry","category-press-releases","tag-cf-research","tag-cf-science","tag-ee-grant","tag-ee-research","tag-new-cf-research","tag-phage-therapy"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/www.emilysentourage.org\/fr_ca\/wp-json\/wp\/v2\/posts\/27094","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.emilysentourage.org\/fr_ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.emilysentourage.org\/fr_ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/fr_ca\/wp-json\/wp\/v2\/users\/1719"}],"replies":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/fr_ca\/wp-json\/wp\/v2\/comments?post=27094"}],"version-history":[{"count":5,"href":"https:\/\/www.emilysentourage.org\/fr_ca\/wp-json\/wp\/v2\/posts\/27094\/revisions"}],"predecessor-version":[{"id":27100,"href":"https:\/\/www.emilysentourage.org\/fr_ca\/wp-json\/wp\/v2\/posts\/27094\/revisions\/27100"}],"wp:attachment":[{"href":"https:\/\/www.emilysentourage.org\/fr_ca\/wp-json\/wp\/v2\/media?parent=27094"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.emilysentourage.org\/fr_ca\/wp-json\/wp\/v2\/categories?post=27094"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.emilysentourage.org\/fr_ca\/wp-json\/wp\/v2\/tags?post=27094"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}